Neuropathie optique étendue en présence d’anticorps
«anti-myelin oligodendrocyte glycoprotein»

Gillard, Florence; ANDRIS, Cécile; LOMMERS, Emilie

Request a copy

Article (Scientific journals)

Neuropathie optique étendue en présence d’anticorps «anti-myelin oligodendrocyte glycoprotein»

Gillard, Florence; ANDRIS, Cécile; LOMMERS, Emilie

2019 • In Revue Médicale de Liège, 74 (4), p. 179-184

Peer reviewed

Permalink
https://hdl.handle.net/2268/234830

PubMed
30997966

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

03 ccl GILLARD (6).pdf

Publisher postprint (1.37 MB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Anti-myelin oligodendrocyte glycoprotein; Anti-aquaporin 4 antibody; Optic neuromyelitis; Optic neuropathy

Abstract :

[en] The discovery of autoantibodies targeting aquaporin-4 (AQP4) of astrocytes has improved the understanding and management of Neuromyelitis Optica Syndrome Disorders (NMO-SD), previously considered as a variant of multiple sclerosis. Later, the detection of MOG IgG1 antibodies, directed against an oligodendrocyte myelin glycoprotein, made it possible to distinguish pathologies with different clinical and prognostic particularities, then helping the clinician in his diagnostic and therapeutic approach. This clinical case aims to feature the clinical differences, prognosis and therapeutic solutions of these pathologies.

Disciplines :

Neurology
Ophthalmology

Author, co-author :

Gillard, Florence ; Université de Liège - ULiège > Master spéc. ophtalmo.

ANDRIS, Cécile ; Centre Hospitalier Universitaire de Liège - CHU > Autres Services Médicaux > Service d'ophtalmologie

LOMMERS, Emilie ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de neurologie

Language :

French

Title :

Neuropathie optique étendue en présence d’anticorps «anti-myelin oligodendrocyte glycoprotein»

Alternative titles :

[en] Extended optic neuropathy with myelin oligodendrocyte glycoprotein antibodies

Publication date :

April 2019

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Belgium

Volume :

Issue :

Pages :

179-184

Peer reviewed :

Peer reviewed

Available on ORBi :

since 26 April 2019

Statistics

Number of views

87 (10 by ULiège)

Number of downloads

3 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

O'Connor KC, McLaughlin KA, De Jager PL, et al.- Self-antigen tetramers discriminate between myelin autoantibodies to native or denaturated protein. Nat Med, 2007, 13, 211-217.
Mader S, Gredler V, Schanda K, et al.- Complement activating antibodies to myelin oligodendrocye glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation, 2011, 8, 184.
Petzold A, Pittock S, Lennon V, et al.- Neuromyelitis optica-IgG (Aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry, 2010, 81, 109-111.
Biotti D, Bonneville F, Tournaire E, et al.- Optic neuritis in patients with anti-MOG antibodiess spectrum disorders: MRI and clinical features from a large multicentric cohort in France. J Neurol, 2017, 264, 2173-2175.
Lennon VA, Kryzer TJ, Pittock SJ, et al.- IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med, 2005, 202, 473-477.
Biotti D, Mahieu L, Bernard-Valnet R, et al.-Spectre de la neuromyélite optique et anticorps anti-MOG. Rev Neurol (Paris), 2015, 171, 181.
Brian G, Weinshenker MD, Dean M, et al.- Neuromyelitis spectrum disorders. Mayo Clin Proc, 2017, 92, 663-679.
Akaishi T, Nakashima I, Takeshita T, et al.- Different étiologies and prognoses of optic neuritis in demyelinating diseases. J Neuroimmunol, 2016, 299, 152-157.
Akaishi T, Sato DK, Nakashima I, et al.- MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study. J Neurol, 2016, 87, 446-448.
Akaishi T, Nakashima I, Takeshita T, et al.- Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica. J Neuroimmunol, 2016, 293, 28-33.
Sato DK, Callegaro D, Lana-Peixoto MA, et al.-Distinction between MOG antibody -positive and AQP4 antibody -positive NMO spectrum disorders. Neurology, 2014, 82, 474-481.
Kitley J, Leite MI, Nakashima I, et al.- Prognostic factors and disease course in Aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the united kingdom and japan. Brain, 2012, 135, 1834-1849.
Ramanathan S, Reddel SW, Henderson A, et al.-Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm, 2014, 1, e40.
Martinez-Hernandez E, Sepulveda M, Rostásy K, et al. Anti-bodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor a1 subunit in patients with isolated optic neuritis. JAMA Neurol, 2015, 72, 187-193.
Nakaruma M, Nakazawa T, Doi H, et al.- Early high - dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefes Arch Clin Exp Ophtalmol, 2010, 248, 1777-1785.
Sato D, Callegaro D, Lana-Peixoto MA, et al.-Treatment of neuromyelitis optica: an evidence based review. Arq Neuropsiquiatr, 2014, 70, 59-66.
Weinshenker BG, O'Brien PC, Petterson TM, et al.- A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol, 1999, 46, 878-886.
Abboud H, Petrak A, Mealy M, et al.- Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Mult Scler, 2016, 22, 185-192.
Wingerchuk DM, Weinshenker BG.- Neuromyelitis optica. Curr Treat Options Neurol, 2008, 10, 55-66.
Kleiter I, Hellwig K, Berthele A, et al.- Neuromyelitis optica study group. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol, 2012, 69, 239-245.
Kimbrough DJ, Fujihara K, Jacob A, et al.- Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord, 2012, 1, 180-187.
Cree Ba, Lamb S, Morgan K, et al.- An open label study or the effect of rituximab in neuromyelitis optica. Neurology, 2005, 64, 1270-1272.
Costanzi C, Matiello M, Lucchinetti CF, et al.-Azathioprine: tolerability, efficacy and predictors of benefits in neuromyelitis optica. Neurology, 2011, 77, 659-666.